These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
24. Relevance of norepinephrine-dopamine interactions in the treatment of major depressive disorder. El Mansari M; Guiard BP; Chernoloz O; Ghanbari R; Katz N; Blier P CNS Neurosci Ther; 2010 Jun; 16(3):e1-17. PubMed ID: 20406250 [TBL] [Abstract][Full Text] [Related]
25. Exercise as an add-on strategy for the treatment of major depressive disorder: a systematic review. Mura G; Moro MF; Patten SB; Carta MG CNS Spectr; 2014 Dec; 19(6):496-508. PubMed ID: 24589012 [TBL] [Abstract][Full Text] [Related]
26. From antioxidant to neuromodulator: The role of ascorbate in the management of major depression disorder. Ferreira NR; Vitorino C; Fortuna A Biochem Pharmacol; 2022 Dec; 206():115300. PubMed ID: 36261067 [TBL] [Abstract][Full Text] [Related]
28. Tachyphylaxis in major depressive disorder: A review of the current state of research. Kinrys G; Gold AK; Pisano VD; Freeman MP; Papakostas GI; Mischoulon D; Nierenberg AA; Fava M J Affect Disord; 2019 Feb; 245():488-497. PubMed ID: 30439676 [TBL] [Abstract][Full Text] [Related]
29. Early improvement as a resilience signal predicting later remission to antidepressant treatment in patients with Major Depressive Disorder: Systematic review and meta-analysis. Wagner S; Engel A; Engelmann J; Herzog D; Dreimüller N; Müller MB; Tadić A; Lieb K J Psychiatr Res; 2017 Nov; 94():96-106. PubMed ID: 28697423 [TBL] [Abstract][Full Text] [Related]
30. Pharmacological Treatment of Cognitive Symptoms in Major Depressive Disorder. Pan Z; Grovu RC; Cha DS; Carmona NE; Subramaniapillai M; Shekotikhina M; Rong C; Lee Y; McIntyre RS CNS Neurol Disord Drug Targets; 2017; 16(8):891-899. PubMed ID: 28933261 [TBL] [Abstract][Full Text] [Related]
32. Nitric oxide: Antidepressant mechanisms and inflammation. Ghasemi M Adv Pharmacol; 2019; 86():121-152. PubMed ID: 31378250 [TBL] [Abstract][Full Text] [Related]
33. Potential Use of MicroRNA for Monitoring Therapeutic Response to Antidepressants. Belzeaux R; Lin R; Turecki G CNS Drugs; 2017 Apr; 31(4):253-262. PubMed ID: 28290081 [TBL] [Abstract][Full Text] [Related]
34. Challenging Treatment-Resistant Major Depressive Disorder: A Roadmap for Improved Therapeutics. de Sousa RT; Zanetti MV; Brunoni AR; Machado-Vieira R Curr Neuropharmacol; 2015; 13(5):616-35. PubMed ID: 26467411 [TBL] [Abstract][Full Text] [Related]
35. Pharmacological treatment of unipolar depressive disorders: summary of WFSBP guidelines. Bauer M; Severus E; Möller HJ; Young AH; Int J Psychiatry Clin Pract; 2017 Sep; 21(3):166-176. PubMed ID: 28367707 [TBL] [Abstract][Full Text] [Related]
36. The Relationship between DNA Methylation and Antidepressant Medications: A Systematic Review. Webb LM; Phillips KE; Ho MC; Veldic M; Blacker CJ Int J Mol Sci; 2020 Jan; 21(3):. PubMed ID: 32012861 [TBL] [Abstract][Full Text] [Related]
37. [The current concept of augmentation of treatment efficiency with antidepressant medication]. Damulin IV; Suvorova IA Zh Nevrol Psikhiatr Im S S Korsakova; 2015; 115(3):106-112. PubMed ID: 26171486 [TBL] [Abstract][Full Text] [Related]
38. Management of chronic depressive patients with residual symptoms. Han C; Yeh TL; Kato M; Sato S; Chang CM; Pae CU CNS Drugs; 2013 May; 27 Suppl 1():S53-7. PubMed ID: 23709362 [TBL] [Abstract][Full Text] [Related]
39. The cholinesterase inhibitor donepezil has antidepressant-like properties in the mouse forced swim test. Fitzgerald PJ; Hale PJ; Ghimire A; Watson BO Transl Psychiatry; 2020 Jul; 10(1):255. PubMed ID: 32712627 [TBL] [Abstract][Full Text] [Related]
40. Benefits of and Barriers to Pharmacogenomics-Guided Treatment for Major Depressive Disorder. Ahmed AT; Weinshilboum R; Frye MA Clin Pharmacol Ther; 2018 May; 103(5):767-769. PubMed ID: 29388201 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]